Evidence map›Paper›PMID 26035588›Full record

ArticleRadiology2015

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

Gary A Ulaner, Debra A Goldman, Craig S Sauter, Jocelyn Migliacci, Joshua Lilienstein, Mithat Gönen, Heiko Schöder, Craig H Moskowitz, Andrew D Zelenetz

Open access · greenAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it

0cells of the map it votes in

12citing papers in PubMed

2.9field-weighted citation impact, top 10% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation UsingClinical lymphoma, myeloma & leukemia · 2023
Trial
BEGEV as Salvage Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Real-World Outcomes and Transplantation Feasibility.Medicina (Kaunas, Lithuania) · 2026
Article
Future direction: molecular imaging-based stem cell research.European journal of nuclear medicine and molecular imaging · 2025
Article
Prognostic value of pre-transplantation total metabolic tumor volume onInternational journal of hematology · 2022
Article
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.Bone marrow transplantation · 2021
Article
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.British journal of haematology · 2020
Article
Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.Journal of global oncology · 2019
Article
Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.Oncotarget · 2018
Review
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.Leukemia & lymphoma · 2018
Article
Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation.Nuclear medicine and molecular imaging · 2018
Article
Reaching 200-ps timing resolution in a time-of-flight and depth-of-interaction positron emission tomography detector using phosphor-coated crystals and high-density silicon photomultipliers.Journal of medical imaging (Bellingham, Wash.) · 2016
Article
Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.Technology in cancer research & treatment
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Gary A UlanerFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Debra A GoldmanFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Craig S SauterFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Jocelyn MigliacciFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Joshua LiliensteinFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Mithat GönenFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Heiko SchöderFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Craig H MoskowitzFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Andrew D ZelenetzFrom the Departments of Radiology (G.A.U., J.L., H.S.), Epidemiology and Biostatistics (D.A.G., M.G.), and Medicine (C.S.S., J.M., C.H.M., A.D.Z.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Departments of Radiology (G.A.U., H.S.) and Medicine (C.S.S., C.H.M., A.D.Z.), Weill Cornell Medical College, New York, NY.

Cornell University · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026

$347.4M

NCI NIH HHS P30 CA008748

6 · The paper itself

Abstract

purposeTo determine the prognostic value of performing fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) before allogeneic and autologous stem cell transplantation (SCT) in patients with aggressive lymphoma. MATERIALS AND

methodsA HIPAA-compliant retrospective review was performed under institutional review board waiver. Patients with aggressive lymphoma underwent allogeneic or autologous SCT between January 2005 and December 2010. FDG PET/CT was performed within the 3 months prior to transplantation. PET/CT images were evaluated for lesions with FDG avidity greater than that of the background liver. The relationship between pretransplantation PET and progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS) was assessed with Kaplan-Meier curves and a corresponding log-rank test for categorical variables and Cox regression for continuous variables.

resultsA total of 175 patients were identified, of whom 73 underwent FDG PET/CT before allogeneic SCT and 102 underwent FDG PET/CT before autologous SCT. Before allogeneic SCT, 23 of 73 patients (32%) had FDG-avid lesions, and before autologous SCT, 11 of 102 patients (11%) had FDG-avid lesions. For allogeneic SCT, the 2-year PFS estimate was 68% (95% confidence interval [CI]: 56%, 82%) in patients without FDG-avid lesions, but only 35% (95% CI: 20%, 61%) for patients with FDG-avid lesions (P = .014). For autologous SCT, the 2-year PFS was 72% (95% CI: 64%, 82%) in patients without FDG-avid lesions, but only 18% (95% CI: 5%, 64%) for patients with FDG-avid lesions (P < .0001). Similar differences were seen in OS and DSS. The risk for posttransplantation recurrence correlated with higher lesional maximum standardized uptake values: for PFS, P < .0001 to P = .01; for DSS, P < .0001 to P = .002; and for OS, P < .0001 to P = .015.

conclusionPerforming FDG PET/CT before SCT in patients with aggressive lymphoma has prognostic value. For patients with aggressive lymphomas, the presence of FDG-avid lesions at PET/CT performed before allogeneic and autologous SCT indicates a lower likelihood of SCT success.

Indexed as

Multimodal ImagingStem Cell TransplantationAdolescentAdultAgedChildFemaleFluorodeoxyglucose F18HumansLymphoma, Non-HodgkinMaleMiddle AgedPositron-Emission TomographyPrognosisRadiographyRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID26035588

DOI10.1148/radiol.2015142556

PMCPMC5006668

OpenAlexW2119091791

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.